Adverse impact of IDH1 and IDH2 mutations in primary AML: Experience of the Spanish CETLAM group

Correlation Between Isocitrate Dehydrogenase Gene Aberrations and Prognosis of Patients with Acute Myeloid Leukemia: A Systematic Review and Meta-Analysis

“…In CN-AML patients with IDH mutations, sensitivity analysis revealed that the study by Nomded eu and colleagues (34) was the source of heterogeneity in pooled HRs for OS and EFS. The followup period in Nomded eu and colleagues (34) (12-72 months) was significantly shorter than that of other studies (approximately 10 years), which brought relatively prolonged OS expectancy of patients with wild-type IDH gene, leading to outlier HR and generating great heterogeneity.…”

Risk factors for relapse after allogeneic transplantation in acute myeloid leukemia

“…Although the prognostic significance has still not been established, some studies have shown a poor outcome. 33,34 RUNX1 mutations RUNX1 mutations are considered to be associated with a poor prognosis. The incidence (8%-16%) is higher in elderly AML and in secondary AML.…”

Prognostic factors for acute myeloid leukaemia in adults - biological significance and clinical use

“…Mutations of the DNA methyltransferase 3A gene (DNMT3A) are considered a negative prognostic factor by most study groups (Ley et al, 2010;Shen et al, 2011;Thol et al, 2011;Yan et al, 2011;Hou et al, 2012;Marcucci et al, 2012;Markova et al, 2012;Renneville et al, 2012;Ribeiro et al, 2012). However, the largest study did not find a prognostic impact (Nomdedeu et al, 2012;Gaidzik et al, 2013). Within CN-AML patients, Gaidzik et al (2013) found a negative prognostic impact in patients with unfavourable molecular risk (CEBPA wt combined with NPM1 wt and/or FLT3-ITD), while Renneville et al (2012) found a negative prognostic effect in patients with favourable molecular risk (CEBPA mutated or NPM1 mutated plus FLT3 no ITD).…”